Showing 2201-2210 of 2314 results for "".
- Jury Awards Allergan Just $48,500 in Trial Over Imprimis False Adshttps://modernod.com/news/jury-awards-allergan-just-48500-in-trial-over-imprimis-false-ads/2476595/A California federal jury ordered Imprimis Pharmaceuticals to pay Allergan for lost profits due to false advertising of its compounded drugs. However, the jury awarded just $48,500 in damages, a small fraction of the millions of dollars that Allergan was seeking. According to a
- Neuropathy May Drive Dry Eye in Migraine Patientshttps://modernod.com/news/neuropathy-may-drive-dry-eye-in-migraine-patients/2476593/Migraine patients with dry eye are more likely to have symptoms suggestive of neuropathy than dry eye patients who don’t have migraines, according to new findings, as reported by Reuters Health. The results raise the possibil
- Novel Approaches to Cataract Surgery are Challenging Phaco; Cost May Determine Their Successhttps://modernod.com/news/novel-approaches-to-cataract-surgery-are-challenging-phaco-cost-may-determine-their-success/2476591/Ultrasonic phacoemulsification (USP) has been the dominant method of cataract surgery globally over the past half century, but novel alternative approaches are attempting to improve or replace it, according to a Market Scope report. These include robotic cataract machines, ultrasonic-less
- Allegro Announces Positive Results of Ex-US Proof-of-Concept Trial With ALG-1007 for Dry Eye Diseasehttps://modernod.com/news/allegro-ophthalmics-announces-positive-results-of-ex-us-proof-of-concept-trial-with-integrin-inhibitor-alg-1007-for-dry-eye-disease/2476583/Allegro Ophthalmics announced positive results of an ex-US proof-of-concept clinical trial of the new investigational ALG-1007 topical drop drug candidate in patients with dry eye disease (DED). The results were presented by Eric D. Donnenfeld, MD, last week at the 2019 American Society of Catara
- MeiraGTx Announces Positive 6-Month Data from Phase 1/2 Trial of Investigational Gene Therapy AAV-RPE65 for RPE65-Deficiencyhttps://modernod.com/news/meiragtx-announces-positive-6-month-data-from-phase-1-2-trial-of-investigational-gene-therapy-aav-rpe65-for-rpe65-deficiency/2476582/MeiraGTx Holdings announced positive data from a phase 1/2 dose escalation trial of AAV-RPE65, the company’s investigational gene therapy for the treatment of RPE65-deficiency, a condition that causes blindness. AAV-RPE65 is a second-generation gene therapy candidate developed specifically to tre
- PECAA Launches the Integrated Eye Care Initiativehttps://modernod.com/news/pecaa-launches-the-integrated-eye-care-initiative/2476579/PECAA, a nationwide doctor alliance group for independent eye care professionals, has launched a new program, the “Integrated Eye Care Initiative,” which is aimed at driving informed decision making for th
- ReGenTree Initiates ARISE-3 (Phase 3) Trial for Dry Eye Syndromehttps://modernod.com/news/regentree-initiates-arise-3-phase-3-trial-for-dry-eye-syndrome/2476577/ReGenTree, a joint venture company between GtreeBNT and RegeneRx Biopharmaceuticals, announced that it initiated a randomized, double masked, placebo-controlled phase 3 clinical trial (ARISE-3) for dry eye syndrome on May 10. The objective of the ARISE-3 study
- Allergan CEO Saunders Wins Vote to Keep Chairman Rolehttps://modernod.com/news/allergan-ceo-saunders-wins-vote-to-keep-chairman-role/2476540/Allergan shareholders have voted down a nonbinding proposal that sought an immediate split of the roles of chairman and chief executive, with 61.3 percent of shareholders backing Chairman and CEO Brent Saunders, as
- Aerie Pharmaceuticals Matches ASCRS Foundation Fund Raising to Provide Sight-Saving Surgeryhttps://modernod.com/news/aerie-pharmaceuticals-matches-ascrs-foundation-fund-raising-to-provide-sight-saving-surgery/2476538/Aerie Pharmaceuticals announced that it is matching, dollar for dollar, the first $30,000 donated to the ASCRS Foundation’s charitable eye care programs by attendees at the 2019 ASCRS-ASOA Annual Meeting, being held in San Diego, from May 3-7, 2019. This is the second year that Aerie is d
- Sydnexis Announces Enrollment of First Patients in Phase 3 Myopia STAAR Study of SYD-101 in Childrenhttps://modernod.com/news/sydnexis-announces-enrollment-of-first-patients-in-phase-3-myopia-staar-study-of-syd-101-in-children/2476532/Sydnexis announced that the first patients have been successfully dosed in a phase 3 multicenter trial of SYD-101, following FDA clearance of Sydnexis’ IND in April. Sydnexis’ STAAR study will be